Agios Pharmaceuticals Inc EV/EBITDA
What is the EV/EBITDA of Agios Pharmaceuticals Inc?
The EV/EBITDA of Agios Pharmaceuticals Inc is N/A
What is the definition of EV/EBITDA?
EV/EBITDA is enterprise value divided by earnings before interest, tax, depreciation, and amortization. It is a measure of how expensive a stock is and is more frequently valid for comparisons across companies than the price to earnings ratio. It measures the price (in the form of enterprise value) an investor pays for the benefit of the company’s cash flow (in the form of EBITDA).
= enterprise value / EBITDA
Price to earnings ratios are impacted by a company's choice of capital structure - companies which raise money via debt will have lower P/Es (and therefore look cheaper) than companies that raise an equivalent amount of money by issuing shares, even though the two companies might have equivalent enterprise values. A sample case is when a company with debt were to raise money by issuing shares of stock, and then used the money to pay off the debt, this company's P/E ratio would shoot up because of the increased number of shares - although nothing about the fundamental value of the business has changed. EV / EBITDA is unaffected by capital structure as enterprise value includes the value of debt, and EBITDA is available to all investors (debt and equity) as it excludes interest payments on that debt. It is ideal for analysts and potential investors looking to compare companies within the same industry.
EV/EBITDA of companies in the Health Care sector on NASDAQ compared to Agios Pharmaceuticals Inc
What does Agios Pharmaceuticals Inc do?
at agios, we are doing incredibly important and difficult work. we are trying to discover and develop breakthrough medicines, and we have a clear motivator — people with cancer and rare genetic diseases who are counting on us to be successful. we are a science-driven research organization. we have built a discovery platform upon our expertise in the fields of cellular metabolism and precision medicine across three major focus areas: cancer metabolism, rare genetic metabolic disorders and metabolic immuno-oncology. it takes people with a diversity of thought, skills, passions and backgrounds to get us from the first stages of understanding new biology and discovering drugs to our ultimate goal of getting these medicines to patients who are waiting for them. our connection to one another and our work and our commitment to our values enable us to potentially change the practice of medicine by by striving for excellence and doing things differently. we call this the "other side of possible
Companies with ev/ebitda similar to Agios Pharmaceuticals Inc
- Perk Labs has EV/EBITDA of N/A
- Canterra Minerals has EV/EBITDA of N/A
- Xortx Therapeutics Inc has EV/EBITDA of N/A
- Comstock Metals Ltd has EV/EBITDA of N/A
- Binovi Technologies has EV/EBITDA of N/A
- RYU Apparel has EV/EBITDA of N/A
- Agios Pharmaceuticals Inc has EV/EBITDA of N/A
- Next Hydrogen Solutions has EV/EBITDA of N/A
- Roots Sustainable Agricultural Technologies has EV/EBITDA of N/A
- Emperor Capital has EV/EBITDA of N/A
- Total Gabon has EV/EBITDA of N/A
- China Uptown has EV/EBITDA of N/A
- Argonaut Resources NL has EV/EBITDA of N/A